Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF | V.TLT.W

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Pressure on stock price.................

<< Previous

Bullboard Posts

Next >>

Comment by CancerSlayeron Mar 08, 2022 4:03am

206 Views

Post# 34493827

RE:RE:RE:RE:Pressure on stock price.................

CancerSlayer wrote:

I don't expect perfect results either, but based on the 70+% CR rate of "evaluable" patients to date who received at least one optimized treatment (11 in total), I selfishly expect at least "near-perfect" results for those patients who receive "two" optimized treatments. Imo, that 70+% 90 day CR rate for that sample size is very likely not a statistical fluke.

I'm also encouraged by the fact that of the two patients who initially received an unoptimized primary treatment, one patient converted from NR to CR status after receiving a subsequent optimized maintenance treatment. This not only indicates the enhanced efficacy of an optimized treatment, but also points to the significant value a future maintenance dose, or two, can offer to the partial responder & the more resistant PR, respectively...resistant PR meaning a patient's PR status persists >90-180 days after a single optimized maintenance treatment.

It is not unreasonable to also think a good percentage of resistant non-responders could ultimately respond if simply given an additional optimized treatment, or if a certain treatment enhancement(s) is made in the form of a dosage adjustment, etc. In the future, it is possible docs find out in practice that the current "two" treatment protocol is simply not sufficient in select cases. JMO.

...two NR patients

<< Previous

Bullboard Posts

Next >>

Silvercorp to expand into Ecuador with C$200M Adventus acquisition